Sanofi’s Tzield (teplizumab) has received expanded approved from the US FDA, allowing it to be used for children aged one ...
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval ...
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and Drug Administration (FDA) to approve Sanofi ...
The U.S. Food and Drug Administration has approved a supplemental biologics license application for Sanofi’s (SNY) Tzield ...
The FDA has approved an expanded indication for the CD3-directed monoclonal antibody teplizumab-mzwv to delay stage 3 type 1 ...
The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.
A new approval in the United States could change the treatment of a serious disease in the youngest patients.
Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...
Sanofi-owned Aventis Pharma has received approval for its type 1 diabetes (T1D) drug, Tzield (teplizumab), from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This authorisation ...
The US Food and Drug Administration (FDA) has approved Sanofi’s supplemental biologic license application for Tzield ...
RED BANK, N.J., Nov. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results